DGAP-News: BB BIOTECH AG / Mot-clé(s) : Bulletin de marché
BB BIOTECH AG: Moderna and its COVID-19 vaccine are representative of the
innovative power of the entire biotech industry
2020-12-16 / 09:40
Media release of December 16, 2020
Market commentary
*Moderna and its COVID-19 vaccine are representative of the innovative power
of the entire biotech industry*
*Moderna, the US company about to launch an mRNA-based COVID-19 vaccine, is
the latest shining example of the progress biotech companies are making for
the good of society. In addition to the highly promising mRNA technology,
molecule design and CRISPR technology were highlighted at BB Biotech's
BioDay, a special event that casts a spotlight on some of the industry's
most promising trends.*
Less than 11 months after the SARS-CoV-2 genome was decoded, the first two
vaccine candidates that could help to bring the global coronavirus pandemic
under control had already been submitted to regulatory authorities for
approval. "The mRNA technology used by Moderna is a good example of how
innovative technologies developed and applied in the labs of biotech
companies are driving medical progress," explains Dr. Daniel Koller, Head of
BB Biotech's Investment Team.
*mRNA technology - preferred method for future vaccine development*
"Our vision is to develop a new generation of medicines," explained Stéphane
Bancel, CEO of Moderna, in his presentation at BB Biotech's BioDay.
Regulatory approval of Moderna's mRNA-1273 vaccine against COVID-19 will
clear the way for other applications with mRNA vaccines. In clinical trials,
Moderna's vaccine was 94.1% effective across all age groups.
An independent advisory board of the US FDA will convene on December 17. The
FDA will decide whether to approve the vaccine 24 to 72 hours after the
board's recommendation is announced. Moderna will market the product on its
own. The company has set up a logistics infrastructure that will allow
international dispatch to commence within 24 hours of approval. US approval
is expected to be granted before the end of 2020. EU regulators are expected
to announce their approval decision in the second week of January. The
COVID-19 vaccine will be produced by the Swiss company Lonza. Up to 20
million doses could be produced in the final weeks of 2020 and one billion
doses in 2021.
Given all the advantages mRNA offers, Bancel is sure it will establish
itself as the technology of choice for vaccine development once the first
product has been approved. The higher probability of response will be a
crucial factor here, Bancel believes. Because human mRNA has the same
chemical structure in all molecules, and mRNA-based drugs differ only in the
coded genetic information they contain, mRNA platforms can be used to
develop a variety of drugs in shorter periods of time. In the case of the
SARS-CoV-2 virus, Moderna took just a few days to select the sequence for
the vaccine from the virus's gene sequence. Another bonus of the mRNA
mechanism is that all vaccines are packaged in the same molecular envelopes,
which makes it easier to produce large volumes. Moreover, unlike the rival
Biontech/Pfizer product, the vaccine can be stored for a period of up to six
months at minus 20 degrees Celsius, 30 days at refrigerator temperatures of
six to eight degrees, and six hours at room temperature.
Through its investment in robotics, IT and production processes, Moderna
has, in the words of Bancel, created the conditions for scaling up all
clinical products that the biotech company brings to the market in the
future. Management had initially planned to reach this milestone in 2023 but
that time frame was shortened by three years thanks to the development and
government funding of its COVID-19 vaccine program. Moderna currently has 13
products in clinical testing, six of which are cancer vaccines and seven
infectious disease vaccines. BB Biotech first invested in Moderna in 2018,
before the company even went public.
*On-screen molecule design*
An alternative novel treatment approach emerging from biotech laboratories
is called molecule design. Relay Therapeutics, which was floated on the
stock exchange in July 2020, is a leader in rational drug design. The
process involves studying the movement of protein molecules to understand
the role of protein motion in causing disease. Relay uses a computational
platform instead of conventional three-dimensional crystal structures.
Machine learning is used for digital simulation and visualization of
chemical and biophysical processes that occur on a timescale of
milliseconds. This is a faster and cheaper way to identify molecules with
potential to be developed as drugs. What's more, molecule design allows more
customized mechanisms of action because properties like pharmacodynamics,
effective dose, bioavailability and toxicity can all be tweaked much more
precisely. Relay Therapeutics is using this technology to develop oral
medications to treat cancer. The most advanced candidate, RLY-1971, is an
SHP2 inhibitor mainly being tested for use in combination with other drugs.
RLY-1971 is currently in the Phase I clinical trial stage. Relay intends to
present topline data for two products in 2021.
*CRISPR fixes genetic defects for good*
The awarding of the Nobel Prize in Chemistry to Emmanuelle Charpentier and
Jennifer A. Doudna in October 2020 underlines the importance of genome
editing as a disruptive technology for future drug development. This
molecular biological tool is used to make targeted changes in the human
genome to cure diseases permanently. Genome editing is already being used
with success in cell-based cancer therapies. In contrast, CRISPR
Therapeutics is a leading exponent of ex-vivo applications of the
CRISPR/Cas9 approach. This involves taking cells from a patient, modifying
them in a lab and re-administering them to the patient. The novelty of the
approach is that fragments of human DNA identified as genetic triggers of
disease are cut out and repaired using genetic replacement parts. The
CRISPR/Cas9 enzyme activates the genetic repair mechanism which every
somatic cell possesses.
BB Biotech has been invested in CRISPR Therapeutics since the first quarter
of 2019. The company is pursuing two clinical trials in beta thalassemia and
sickle cell anemia in cooperation with Vertex Pharma, a core position in BB
Biotech's portfolio. Both diseases are inherited genetic disorders that
result in the defective formation of blood cells with severe progression.
The genetically modified stem cells that were administered back to the
patients led to a complete cure. In addition to these two clinical trials,
CRISPR Therapeutics is pursuing three cell-based projects in immuno-oncology
on its own.
*For further information:*
*Media Relations*
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland,
tel. +41 44 267 67 00
Tanja Chicherio, [1]tch@bellevue.ch
www.bbbiotech.com [2]
*Company profile*
BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland
and listed on the stock exchanges in Switzerland, Germany and Italy. Since
1993, the company has invested in innovative drug development companies that
are mainly located in the US and Western Europe. BB Biotech is one of the
leading investors in this sector. BB Biotech builds on the long-standing
experience of its distinguished Board of Directors and on the fundamental
analysis of the experienced Investment Management Team of Bellevue Asset
Management AG when making its investment decisions.
*Disclaimer *
This release contains forward-looking statements and expectations as well as
assessments, beliefs and assumptions. Such statements are based on the
current expectations of BB Biotech, its directors and officers, and are,
therefore, subject to risks and uncertainties that may change over time. As
actual developments may significantly differ, BB Biotech and its directors
and officers accept no responsibility in that regard. All forward-looking
statements included in this release are made only as of the date of this
release and BB Biotech and its directors and officers assume no obligation
to update any forward-looking statements as a result of new information,
future events or other factors.
2020-12-16 Communiqué de presse transmis par Tensid EQS AG. www.eqs.com
L'éditeur est responsable pour le contenu de la nouvelle.
Langue : Français
Entreprise : BB BIOTECH AG
Schwertstrasse 6
8200 Schaffhausen
Schweiz
Téléphone : +41 52 624 08 45
E-mail : info@bbbiotech.com
Site internet : www.bbbiotech.ch
ISIN : CH0038389992
Numéro valeur : A0NFN3
Bourses : Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, Hamburg, Hannover, München,
Stuttgart; SIX
EQS News ID : 1155390
Fin du message DGAP News-Service
1155390 2020-12-16
1: mailto:tch@bellevue.ch
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=f80c4feec698b1c5fa8ce919781cfb2a&application_id=1155390&site_id=vwd&application_name=news
(END) Dow Jones Newswires
December 16, 2020 03:40 ET (08:40 GMT)